2017
Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission
Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, Srinivasan A, Pettigrew MM, Thom KA. Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission. Antimicrobial Agents And Chemotherapy 2017, 62: 10.1128/aac.01631-17. PMID: 29133567, PMCID: PMC5740370, DOI: 10.1128/aac.01631-17.Peer-Reviewed Original ResearchConceptsMedical intensive care unitSurgical intensive care unitIntensive care unitICU admissionRisk factorsCare unitIntensive care unit admissionBroad-spectrum antibiotic useMultidrug-resistant Acinetobacter baumanniiPositive clinical cultureCare unit admissionRetrospective cohort analysisAssociated risk factorsEmpirical antibiotic selectionInfection control practicesPrevalence of MDRMaryland Medical CenterPerirectal surveillance culturesImportant nosocomial pathogenUnit admissionAdult patientsICU typePrevious admissionsCurrent hospitalizationActive surveillance
2013
Panel 6: Vaccines
Pelton SI, Pettigrew MM, Barenkamp SJ, Godfroid F, Grijalva CG, Leach A, Patel J, Murphy TF, Selak S, Bakaletz LO. Panel 6: Vaccines. Otolaryngology 2013, 148: e90-e101. PMID: 23536534, PMCID: PMC4029613, DOI: 10.1177/0194599812466535.Peer-Reviewed Original ResearchConceptsAcute otitis mediaPneumococcal conjugate vaccineOtitis mediaDevelopment of correlatesCandidate antigensAnimal modelsClinical efficacy trialsEffectiveness of vaccinesBurden of diseaseNontypeable Haemophilus influenzaeHuman clinical trialsOtitis pathogensConjugate vaccineVaccine strategiesPneumococcal serotypesClinical trialsMoraxella catarrhalisAdditional serotypesNew adjuvantsEfficacy trialsObservational studyFrequent recurrenceChild healthVaccine antigensMore antigens